Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger?

After Bristol-Myers Squibb and activist investor Starboard Value released dueling presentations on the planned $74 billion merger with Celgene earlier this week, Wall Street analysts started speculating about what might actually cause the deal to go south...
Login to comment.